ImmunoGenesis to Present IND-Enabling Development Progress and Therapeutic Potential of IMGS-203, a Novel STING Agonist, at SITC 2026 Annual Meeting

The Quick Take
HOUSTON, Nov. 4, 2026 /PRNewswire/ -- ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced upcoming presentations describing the IND-enabling activities and therapeutic potential for IMGS-203, the company's novel Stimulator...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Local
LGI Homes Q3 2026 earnings reveal leadership test in downturn
SG&A ratio improved 180 bps year over year, while backlog fell 47.5% and guidance narrowed to 4,600 to 4,800 closings
Business
Graybar Named One of America's Top 100 Most Loved Workplaces® for 2026
ST. LOUIS, Nov. 4, 2026 /PRNewswire/ -- Graybar, a leading distributor of electrical, industrial, automation and connectivity products, has been named to the…
Business
Mesirow Advises Canworks on its Sale to Mason Wells
Rick Weil, Melanie Yermack and Christopher Yike served as transaction leads. Canworks, Inc. is a leading digital printer for the beverage industry. Mesirow…
Business
